PCM
NMTR

Prelude Capital Management’s 9 Meters Biopharma NMTR Stock Holding History

Prelude Capital Management’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500
Closed -$12K – 2072
2021
Q1 		$12K Buy
+500
New +$15.4K ﹤0.01% 1483

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's NMTR Position: Q2 2021 in Review

Prelude Capital Management sold out of 9 Meters Biopharma (NMTR) in Q2 2021, closing a stake of 500 shares — an estimated $12K sold.

Prelude Capital Management first reported a position in NMTR in Q1 2021 and held it in 1 quarter. The position peaked at $12K in Q1 2021. 99 funds tracked by Wall St. Rank hold NMTR as of Q2 2021.

  • Prelude Capital Management reported no remaining 9 Meters Biopharma position as of Q2 2021 after selling out during the quarter.
  • Prelude Capital Management sold 500 9 Meters Biopharma shares in Q2 2021, an estimated $12K.
  • Prelude Capital Management first reported a position in 9 Meters Biopharma in Q1 2021 and held it in 1 quarter.
  • Prelude Capital Management's 9 Meters Biopharma position peaked at $12K in Q1 2021.
  • 99 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2021.

Based on Prelude Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.